Shares of Oruka Therapeutics Inc. (ORKA) are down nearly 48% from their 52-week high of $31.13, recorded last October, and trade around $16.
This biotechnology company is developing novel biologics for chronic skin diseases. Its lead investigational biologics, ORKA-001 and ORKA-002, are designed to block cytokines that play key roles in the pathogenesis of psoriasis and other inflammatory diseases.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.